The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Following this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa continue to perform well and are contributing to a total of EUR1.4 billion in sales for this quarter alone. These results show ...

Antisemitic assaults on visiting Israeli soccer fans, and incendiary chants and attacks by some Israelis: Here’s what we know so far about the violence in Amsterdam last week. By Jim ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...